Currently, a variety of AXL‐targeting agents, including small molecules, monoclonal antibodies, antibody‐drug conjugates, and soluble receptors, are in various stages of clinical trials in both solid tumors and AML. The gene discussed is AXL; the disease is acute myeloid leukemia.